EP1931359A4 - Combination therapy for controlled carbohydrate digestion - Google Patents

Combination therapy for controlled carbohydrate digestion

Info

Publication number
EP1931359A4
EP1931359A4 EP06803558A EP06803558A EP1931359A4 EP 1931359 A4 EP1931359 A4 EP 1931359A4 EP 06803558 A EP06803558 A EP 06803558A EP 06803558 A EP06803558 A EP 06803558A EP 1931359 A4 EP1931359 A4 EP 1931359A4
Authority
EP
European Patent Office
Prior art keywords
combination therapy
carbohydrate digestion
controlled carbohydrate
controlled
digestion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06803558A
Other languages
German (de)
French (fr)
Other versions
EP1931359A2 (en
Inventor
Alan Watson
Laura Brass
Bard J Geesaman
Vaughn Kailian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elixir Pharmaceuticals Inc
Original Assignee
Elixir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Pharmaceuticals Inc filed Critical Elixir Pharmaceuticals Inc
Publication of EP1931359A2 publication Critical patent/EP1931359A2/en
Publication of EP1931359A4 publication Critical patent/EP1931359A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06803558A 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion Withdrawn EP1931359A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71753605P 2005-09-14 2005-09-14
PCT/US2006/035761 WO2007033292A2 (en) 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion

Publications (2)

Publication Number Publication Date
EP1931359A2 EP1931359A2 (en) 2008-06-18
EP1931359A4 true EP1931359A4 (en) 2009-04-01

Family

ID=37865568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06803558A Withdrawn EP1931359A4 (en) 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion

Country Status (4)

Country Link
EP (1) EP1931359A4 (en)
CN (1) CN101325959A (en)
CA (1) CA2622558A1 (en)
WO (1) WO2007033292A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101380813B1 (en) * 2005-04-20 2014-04-04 깃세이 야쿠힌 고교 가부시키가이샤 Combined pharmaceutical preparation for treatment of type 2 diabetes
CA2628506A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032011A2 (en) * 2004-09-14 2006-03-23 Elixir Pharmaceuticals, Inc. Combination therapy for controlled carbohydrate digestion
WO2006134492A2 (en) * 2005-04-12 2006-12-21 Agi Therapeutics Research Limited Acarbose methods and formulations for treating chronic constipation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3543999A1 (en) * 1985-12-13 1987-06-19 Bayer Ag HIGH PURITY ACARBOSE
US4898986A (en) * 1986-09-09 1990-02-06 Takeda Chemical Industries, Ltd. Inosose derivatives, production and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032011A2 (en) * 2004-09-14 2006-03-23 Elixir Pharmaceuticals, Inc. Combination therapy for controlled carbohydrate digestion
WO2006134492A2 (en) * 2005-04-12 2006-12-21 Agi Therapeutics Research Limited Acarbose methods and formulations for treating chronic constipation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOLMAN R R ET AL: "A RANDOMIZED DOUBLE-BLIND TRIAL OF ACARBOSE IN TYPE 2 DIABETES SHOWS IMPROVED GLYCEMIC CONTROL OVER 3 YEARS (U.K. PROSPECTIVE DIABETES STUDY 44)", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 22, no. 6, 1 June 1999 (1999-06-01), pages 960 - 964, XP008000344, ISSN: 0149-5992 *
KLEIST P ET AL: "CONCOMITANT ADMINISTRATION OF THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) DOES NOT ALTER THE PHARMACOKINETICS OF GLIBENCLAMIDE", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, vol. 53, no. 2, 1 October 1997 (1997-10-01), pages 149 - 152, XP009045647, ISSN: 0031-6970 *
WELBORN T A: "ACARBOSE, AN ALPHA-GLUCOSIDASE INHIBITOR FOR NON-INSULIN-DEPENDENT DIABETES", MEDICAL JOURNAL OF AUSTRALIA, AUSTRALIAN MEDICAL PUB., SYDNEY, AU, vol. 168, no. 2, 19 January 1998 (1998-01-19), pages 76 - 78, XP008034334, ISSN: 0025-729X *

Also Published As

Publication number Publication date
EP1931359A2 (en) 2008-06-18
CA2622558A1 (en) 2007-03-22
CN101325959A (en) 2008-12-17
WO2007033292A2 (en) 2007-03-22
WO2007033292A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
IL196559A0 (en) Combination therapy
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
IL196556A0 (en) Combination therapy
EP1986745A4 (en) Unfiltered radiation therapy
EP2054061A4 (en) Combination therapy
GB0504206D0 (en) Combination therapy
GB0524103D0 (en) Healing
GB0509052D0 (en) Combination therapy
IL198026A0 (en) Sequential combination therapy
ZA200709627B (en) Combination therapy
ZA200902203B (en) Combination therapy
GB0511769D0 (en) Treatment
GB0507003D0 (en) Therapeutic
GB0518720D0 (en) Therapeutic combination
GB0502171D0 (en) Well treatment
EP1931359A4 (en) Combination therapy for controlled carbohydrate digestion
GB0525535D0 (en) Tumour treatment
GB0507685D0 (en) Cancer treatment
GB0526132D0 (en) Combination Therapy
GB0526121D0 (en) Combination therapy
GB0500658D0 (en) Combination therapy
GB0513778D0 (en) Combination therapy
GB0506726D0 (en) Combination therapy
GB0514347D0 (en) Combination therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080312

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KAILIAN, VAUGHN

Inventor name: GEESAMAN, BARD, J.

Inventor name: BRASS, LAURA

Inventor name: WATSON, ALAN

A4 Supplementary search report drawn up and despatched

Effective date: 20090304

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 15/12 20060101ALI20090226BHEP

Ipc: A61K 31/715 20060101AFI20080402BHEP

Ipc: A61P 3/10 20060101ALI20090226BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090603